Loading…
Exicure Inc Is A Clinical-Stage Biotechnology Company Focused On Developing Treatments For Blood-Related Diseases, With An Emphasis On Small-Molecule Therapies That Have The Potential To Benefit A Broad Range Of Patients. The Company Acquired Gpcr Therapeutics Usa And Secured A License For Gpc-100 (Burixafor), A Clinical-Stage Small-Molecule Compound That Inhibits The Chemokine Receptor Cxcr4. Gpc-100 Has Demonstrated The Ability To Effectively Mobilize Various Cell Types, Including Hematopoietic Stem Cells And Lymphocytes, Highlighting Its Broad Therapeutic Potential Across Multiple Indications.